ERBB2 and breast carcinoma: The potential clinical relevance of HER-2 expression in NSCLC is currently under evaluation [13], however, the recent role of HER-2 amplification in the acquisition of resistance to TKI, reported in 12-13% of patients [11,14], may render HER-2 a potential target not only in breast cancer but also in NSCLC.